158 related articles for article (PubMed ID: 15194556)
1. Edema of the eyelids and sclera after rituximab infusion for orbital MALT lymphoma.
Oribe N; Tanimoto TE; Shimoda K; Hikiji W; Mitsugi K; Takase K; Henzan H; Numata A; Miyamoto T; Fukuda T; Nagafuji K; Harada M
Haematologica; 2004 Jun; 89(6 Suppl):EIM14. PubMed ID: 15194556
[No Abstract] [Full Text] [Related]
2. [Serum sickness induced by rituximab infusion; report of two cases with hematological malignancies].
Matsui T; Hidaka M; Kawakita T; Inoue Y; Sakai T; Harada N; Takemoto S; Nagakura S; Tsukamoto A; Kiyokawa T; Kawano F
Rinsho Ketsueki; 2009 Apr; 50(4):304-8. PubMed ID: 19404025
[TBL] [Abstract][Full Text] [Related]
3. Rituximab as first line treatment for MALT lymphoma of extraocular muscles.
Benetatos L; Alymara V; Asproudis I; Bourantas KL
Ann Hematol; 2006 Sep; 85(9):625-6. PubMed ID: 16691396
[No Abstract] [Full Text] [Related]
4. [A case of primary mucosa-associated lymphoid tissue lymphoma of the bladder regressed after rituximab in combination with CHOP chemotherapy].
Kakuta Y; Katoh T; Saitoh J; Yazawa K; Hosomi M; Itoh K
Hinyokika Kiyo; 2006 Dec; 52(12):951-4. PubMed ID: 17252980
[TBL] [Abstract][Full Text] [Related]
5. Intra-CSF rituximab for lymhomatous meningitis.
Chamberlain MC; Glantz MJ
J Clin Oncol; 2007 Oct; 25(28):4508-9; author reply 4509-11. PubMed ID: 17906219
[No Abstract] [Full Text] [Related]
6. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
[TBL] [Abstract][Full Text] [Related]
7. Eight-cycle rituximab therapy resulted in complete remission in primary cutaneous marginal zone lymphoma.
Seker M; Ustaalioğlu BB; Bilici A; Yildirim ME; Kefeli U; Barisik NO; Tamer I; Gumus M
Leuk Res; 2010 Jul; 34(7):e160-3. PubMed ID: 20219245
[No Abstract] [Full Text] [Related]
8. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma.
Pijpe J; van Imhoff GW; Vissink A; van der Wal JE; Kluin PM; Spijkervet FK; Kallenberg CG; Bootsma H
Ann Rheum Dis; 2005 Jun; 64(6):958-60. PubMed ID: 15576414
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
Xia ZJ; Wang FH; Huang HQ; Luo HY; Li YH; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):490-4. PubMed ID: 16613687
[TBL] [Abstract][Full Text] [Related]
10. [Extranodal marginal zone lymphoma of the ocular adnexa].
Møller A; Specht L; Toft PB; Sjø LD
Ugeskr Laeger; 2008 Nov; 170(45):3660-3. PubMed ID: 18986616
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa.
Ferreri AJ; Ponzoni M; Martinelli G; Muti G; Guidoboni M; Dolcetti R; Doglioni C
Haematologica; 2005 Nov; 90(11):1578-9. PubMed ID: 16266908
[TBL] [Abstract][Full Text] [Related]
12. Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren's syndrome.
Harner KC; Jackson LW; Drabick JJ
Rheumatology (Oxford); 2004 Oct; 43(10):1309-10. PubMed ID: 15448217
[No Abstract] [Full Text] [Related]
13. Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas.
Rigacci L; Nassi L; Puccioni M; Mappa S; Polito E; Dal Pozzo S; Alterini R; Carrai V; Puccini B; Bosi A
Ann Hematol; 2007 Aug; 86(8):565-8. PubMed ID: 17483948
[TBL] [Abstract][Full Text] [Related]
14. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy.
Martinelli G; Laszlo D; Ferreri AJ; Pruneri G; Ponzoni M; Conconi A; Crosta C; Pedrinis E; Bertoni F; Calabrese L; Zucca E
J Clin Oncol; 2005 Mar; 23(9):1979-83. PubMed ID: 15668468
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine combinations for patients with advanced marginal zone lymphomas--best treatment option or too toxic?
Peinert S; Carney D; Prince HM; Januszewicz EH; Seymour JF
Br J Haematol; 2009 Sep; 146(6):685-6. PubMed ID: 19638019
[No Abstract] [Full Text] [Related]
16. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva.
Nückel H; Meller D; Steuhl KP; Dührsen U
Eur J Haematol; 2004 Oct; 73(4):258-62. PubMed ID: 15347312
[TBL] [Abstract][Full Text] [Related]
17. Enteroviral encephalitis in a patient with a marginal zone lymphomatreated with rituximab.
Schilthuizen C; Berenschot HW; Levin MD
Neth J Med; 2010 May; 68(5):221-3. PubMed ID: 20508271
[TBL] [Abstract][Full Text] [Related]
18. Ventricular tachycardia associated with infusion of rituximab in mantle cell lymphoma.
Arai Y; Tadokoro J; Mitani K
Am J Hematol; 2005 Apr; 78(4):317-8. PubMed ID: 15795913
[No Abstract] [Full Text] [Related]
19. [MALT (mucosa-associated lymphoid tissue) lymphoma of the lacrimal gland].
Roussel B; Bettembourg O; Cochard C; Cochener B
J Fr Ophtalmol; 2007 Nov; 30(9):961-5. PubMed ID: 18046283
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature.
Jäger G; Höfler G; Linkesch W; Neumeister P
Haematologica; 2004 Apr; 89(4):ECR01. PubMed ID: 15075093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
